CVS Health launches Eli Lilly GLP-1 partnership, raises outlook
The pharmacy chain reported higher profit alongside the incretin tie-up, according to the Wall Street Journal.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 5 03:00 ETSource: WSJ
The wire
- 01CVS Health said it is launching a GLP-1 partnership with Eli Lilly and lifted its full-year outlook as profit increased.
- 02Retail and PBM channel deals shape patient access and pricing for branded semaglutide and tirzepatide alternatives to compounded supply.
- 03Terms, covered products and launch timing were not detailed in the available report.
From the source
Read at wsj.comCVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases